CIDRAP newsletters options
Of 951,033 screenings performed, only 0.07% indicated COVID risk.
Study suggests medical masks may offer similar protecion as N95 respirators, but experts say hold on.
Six states reported more highly pathogenic avian flu outbreaks in poultry flocks over the past few days, including three that reported large losses in commercial poultry, according to updates from the US Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS).
The outbreak is unusual in its scale and seasonality.
Compared to 2020, mortality rates due to COVID-19 among young adults increased significantly in 2021.
More than 70% of outpatient antibiotic prescriptions from primary healthcare facilities were inappropriate.
Adapting COVID-19 standards of care to evolving information about optimal treatments may have shortened recovery and reduced deaths.
Rates of antimicrobial resistance in urinary E coli isolates are rising in both hospitals and the community.
A large international study found antibiotic use in newborns was disproportinate compared with the burden of early-onset sepsis.
The research team was surprised at how prevalent stigma was, with levels higher in those with a clinical diagnosis.
Flu activity is very high or high across most of the continental United States.
The agreement paves the way for bold, specific committments at a UN high level AMR meeting in 2024.
The latest case is the stillborn baby of a mother who survived Ebola.
The changes target racist and stigmitizing language surrounding a term that came into use in 1970.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
Originally published by CIDRAP News Nov 23
The boosters confer 28% to 56% more protection against symptomatic infections than 2 to 4 doses of the original vaccines, a new study estimates.
Protection against Omicron reinfection was lowest, at 60%.
Of 35 million who have gotten their booster shots, 16 million were seniors.
The trial will investigate whether an early IV-to-oral transition improves outcomes in patients with gram-negative bloodstream infections.
Adult US COVID-19 patients who received the antiviral drug Paxlovid within 5 days after diagnosis had a 51% lower hospitalization rate than nonrecipients.
